13F-HR filed by Opaleye Management Inc.
Opaleye Management Inc. filed this 13F-HR for the quarter ended 2024-03-31, filed 2024-05-15, with 51 holding rows worth $436,932,852.
- Accession
- 0001493152-24-019869
- Filer
- CIK 1595855
- Filed
- 2024-05-15
- Accepted by EDGAR
- acceptance time not in the bulk data set
- Ingested
- Source
- SEC quarterly data set
13F report for Q1 2024
A holdings report, 51 entries on the cover page, a total value of $436,932,852 stated on the cover page (in dollars after the unit check, H1), rows summing to $436,932,852 with VALUE read as dollars as filed, 13F file number 028-15896. A later restatement replaced it, so the quarter does not use it. The resolved quarter.
The information table after summing rows of one CUSIP and put or call (H4), with the CUSIP and issuer name as filed. Values in dollars after the unit check (method).
| Issuer as filed | CUSIP | Class | Amount | Value | Value read as | Type |
|---|---|---|---|---|---|---|
| OCULAR THERAPEUTIX INC | 67576A100 | COM | 6,653,138 | $60,543,556 | dollars as filed | |
| HARROW INC | 415858109 | COM | 3,920,600 | $51,869,538 | dollars as filed | |
| TG THERAPEUTICS INC COM | 88322Q108 | Stock | 2,280,000 | $34,678,800 | dollars as filed | |
| KEROS THERAPEUTICS INC COM | 492327101 | Stock | 367,500 | $24,328,500 | dollars as filed | |
| RHYTHM PHARMACEUTICALS INC | 76243J105 | COM | 515,000 | $22,314,950 | dollars as filed | |
| CATALYST PHARMACEUTICALS INC | 14888U101 | COM | 1,004,355 | $16,009,419 | dollars as filed | |
| ARVINAS INC | 04335A105 | COM | 330,000 | $13,622,400 | dollars as filed | |
| IOVANCE BIOTHERAPEUTICS INC | 462260100 | COM | 897,000 | $13,293,540 | dollars as filed | |
| JASPER THERAPEUTICS INC | 471871202 | COM NEW | 435,573 | $12,788,423 | dollars as filed | |
| EDGEWISE THERAPEUTICS INC | 28036F105 | COM | 665,000 | $12,129,600 | dollars as filed | |
| 4D MOLECULAR THERAPEUTICS INC COM | 35104E100 | Stock | 344,123 | $10,963,759 | dollars as filed | |
| CODEXIS INC | 192005106 | COM | 3,120,000 | $10,888,800 | dollars as filed | |
| PROTARA THERAPEUTICS INC | 74365U107 | COM STK | 2,692,594 | $10,797,302 | dollars as filed | |
| ACELYRIN INC | 00445A100 | COM | 1,580,000 | $10,665,000 | dollars as filed | |
| ETON PHARMACEUTICALS INC | 29772L108 | COMMON STOCK | 2,445,781 | $9,171,679 | dollars as filed | |
| TREVI THERAPEUTICS INC COM | 89532M101 | Stock | 2,645,000 | $9,125,250 | dollars as filed | |
| LYELL IMMUNOPHARMA INC | 55083R104 | COM | 3,355,000 | $7,481,650 | dollars as filed | |
| NEWAMSTERDAM PHARMA CO NV | N62509109 | COMMON STOCK | 315,388 | $7,458,926 | dollars as filed | |
| Ventyx Biosciences Inc | 92332V107 | Common Stock | 1,285,000 | $7,067,500 | dollars as filed | |
| INTELLIA THERAPEUTICS INC | 45826J105 | COM | 255,000 | $7,015,050 | dollars as filed | |
| COMPASS THERAPEUTICS INC | 20454B104 | COM | 3,170,000 | $6,276,600 | dollars as filed | |
| XOMA ROYALTY CORPORATION | 98419J206 | COMMON STOCK | 250,000 | $6,012,500 | dollars as filed | |
| LIQUIDIA CORPORATION COM NEW | 53635D202 | Stock | 395,000 | $5,826,250 | dollars as filed | |
| VAXCYTE INC COM | 92243G108 | Stock | 85,000 | $5,806,350 | dollars as filed | |
| NYXOAH S A | B6S7WD106 | SHS | 320,000 | $4,316,800 | dollars as filed | |
| SAVARA INC | 805111101 | COM | 855,000 | $4,257,900 | dollars as filed | |
| SYROS PHARMACEUTICALS INC | 87184Q206 | COM NEW | 787,545 | $4,212,831 | dollars as filed | |
| UROGEN PHARMA LTD | M96088105 | COMMON STOCK | 270,000 | $4,050,000 | dollars as filed | |
| REVANCE THERAPEUTICS INC | 761330109 | COM | 785,000 | $3,862,200 | dollars as filed | |
| Applied Therapeutics Inc | 03828A101 | Common Stock | 1,770,000 | $3,659,875 | dollars as filed | |
| RELMADA THERAPEUTICS INC | 75955J402 | COMMON STOCK | 759,000 | $3,529,350 | dollars as filed | |
| PROTAGONIST THERAPEUTICS | 74366E102 | COM | 112,700 | $3,260,411 | dollars as filed | |
| GOSSAMER BIO INC | 38341PAA0 | NOTE 5.000% 6/0 | 8,000,000 | $3,212,928 | dollars as filed | principal |
| ZENTALIS PHARMACEUTICALS INC | 98943L107 | COMMON STOCK | 200,000 | $3,152,000 | dollars as filed | |
| ALLAKOS INC | 01671P100 | COM | 2,435,000 | $3,068,100 | dollars as filed | |
| GOSSAMER BIO INC COM | 38341P102 | Stock | 2,440,109 | $2,879,329 | dollars as filed | |
| IBIO INC | 451033708 | CMN | 680,000 | $2,760,800 | dollars as filed | |
| VERASTEM INC | 92337C203 | COMMON STOCK | 211,400 | $2,494,520 | dollars as filed | |
| ALIGOS THERAPEUTICS INC COM NEW | 01626L105 | Stock | 1,630,000 | $1,597,400 | dollars as filed | |
| CONTEXT THERAPEUTICS INC | 21077P108 | COM | 1,108,357 | $1,529,533 | dollars as filed | |
| PRECIGEN INC | 74017N105 | COM | 947,500 | $1,373,875 | dollars as filed | |
| LARIMAR THERAPEUTICS INC | 517125100 | COM | 174,413 | $1,323,795 | dollars as filed | |
| FULCRUM THERAPEUTICS INC | 359616109 | COMMON STOCK | 130,000 | $1,227,200 | dollars as filed | |
| MORPHOSYS AG | 617760202 | ADR | 65,000 | $1,179,100 | dollars as filed | |
| GLAUKOS CORP COM | 377322102 | Stock | 8,576 | $808,631 | dollars as filed | |
| PMV PHARMACEUTICALS INC | 69353Y103 | COM | 471,481 | $802,130 | dollars as filed | |
| BIODESIX INC | 09075X108 | COM | 534,657 | $764,560 | dollars as filed | |
| REGULUS THERAPEUTICS INC | 75915K309 | COM | 170,308 | $490,487 | dollars as filed | |
| DESIGN THERAPEUTICS INC | 25056L103 | COM | 113,038 | $455,543 | dollars as filed | |
| REPARE THERAPEUTICS INC | 760273102 | COM | 67,561 | $318,212 | dollars as filed | |
| CRINETICS PHARMACEUTICALS INC COM | 22663K107 | Stock | 210,000 | $210,000 | dollars as filed |
Amendment chain
| Filing | Role | Filed | Accepted | Ingested |
|---|---|---|---|---|
| 13F-HR 0001493152-24-019869 | this filing | 2024-05-15 | acceptance time not in the bulk data set | |
| 13F-HR/A 0001493152-24-021780 | base | 2024-05-29 | acceptance time not in the bulk data set |